Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EJErin Jou

Discussion

Loading...

Member takes

Overview

Review shows poor outcomes in TP53-mutated AML with hypomethylating agents and venetoclax, indicating need for better induction therapy selection.

Key Points

  • This review assesses the impact of TP53 allelic status on treatment outcomes in TP53-mutated acute myeloid leukemia.
  • Queried electronic medical records for AML patients with TP53 mutations from 2019 to 2024.
  • Classified TP53 allelic status using next generation sequencing and cytogenetic testing.
  • Measured survival outcomes using Kaplan-Meier analysis and log-rank testing.
  • 104 out of 957 AML cases had TP53 mutations.
  • Median overall survival for TP53-mutated patients was 5.9 months.
  • Intensive therapy showed longer mOS for single-hit patients compared to double-hit patients.

Cite This Study

Erin Jou (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3dchttps://doi.org/10.1182/blood-2025-1705
View Full Paper
Ask AI
Bookmark
Share